Peripheral Neuropathy vs. Polyneuropathy

by Dr. Richard Mann, DABPS, ret, Chief Scientific Officer and Founder, Realm Labs®, sole US distributor of the NeuRemedy® line of benfotiamine products for the healthy function of the nerves in the feet and legs*

Which one of the following statements is true?
A. Peripheral neuropathy and polyneuropathy are the same things.
B. Peripheral neuropathy is a type of polyneuropathy.
C. Polyneuropathy is a type of peripheral neuropathy.

According to the National Institute of Neurological Disorders and Stroke, peripheral neuropathy refers to the many varied conditions that involve damage to the peripheral nervous system. Examples of peripheral neuropathy would include tarsal tunnel syndrome, neuromas, trigeminal neuralgia, radiculopathies and polyneuropathy.

Polyneuropathy is the most common type of peripheral neuropathy. It is a progressive length dependent dysfunction of the peripheral nervous system that usually starts in the great toes and ascends up the feet and legs over time in a stocking/glove distribution.  It is sometimes described as a dying back phenomenon affecting the peripheral nervous system.  A case could be made that polyneuropathy is a neurodegenerative disease, but this term is often reserved for central nervous system diseases such as Alzheimer’s disease or Parkinson’s disease.  Polyneuropathy is characterized by burning, tingling, numbness, and/or shooting pains.  It is the most common and often the first complication associated with diabetes.  Polyneuropathy is also commonly associated with prediabetes, chemotherapy, alcoholism, HIV infection and advanced age.

The mechanism by which peripheral neurons dysfunction in polyneuropathy is complex, multifactorial and the subject of ongoing research. One very intriguing theory posits that polyneuropathy is associated with decreased energy availability to the peripheral neurons. This would explain why many common causes of polyneuropathy (diabetes, alcoholism, chemotherapy, HIV infection, etc.) are associated with decreased intraneuronal energy availability; either due to damaged mitochondria, the energy generating organelle of the cell, or a deficiency in thiamine (vitamin B1) or vitamin B12, nutrients essential in the generation of energy from carbohydrates.

The correct answer is:
C. Polyneuropathy is a type of peripheral neuropathy.
So, when a patient presents with bilateral numbness, tingling, burning, and/or shooting pains starting in the toes and gradually ascending up the feet and legs, consider the diagnosis of polyneuropathy.Previously published Clinical Updates can be found at: https://drrichardhmann.com/


A request from the author:
Have any of your patients who have taken NeuRemedy experienced any benefits in addition to improvement in their neuropathic symptoms? If so, I would like to know. Please contact me at rhm123@gmail.com or call me at 561-549-9099.


Dr. Mann bust-shot

Dr. Richard H Mann, DABPS, ret
Chief Scientific Officer & Founder, Realm Labs

If you would like to speak with Dr. Mann about how to improve your outcomes in the treatment of polyneuropathy call 866-634-2745 or email Dr. Mann at realmlabs123@gmail.com

Dr. Mann is the developer of the  NeuRemedy®line of benfotiamine nutritional supplements. NeuRemedy is a safe, proven, and effective nutritional formulation dispensed by physicians to their patients suffering from numbness, tingling, burning and/or shooting pains in the feet and legs. These symptoms are commonly associated with diabetes, prediabetes, advanced age, chronic alcohol consumption, and chemotherapy. Thiamine (vitamin B1) deficiency often accompanies and intensifies these symptoms. The reversal of thiamine deficiency is an important therapeutic goal in the management of these patients.*

The key ingredient in NeuRemedy, benfotiamine, is the most highly bioactive oral form of thiamine available. It rapidly and safely reverses thiamine deficiency, improving the functioning of the nerves in the feet and legs. Each capsule of NeuRemedy contains 150 mg of benfotiamine in a proprietary formulation. Because of its impressive success rate and high safety profile, NeuRemedy was recently licensed in Canada as an important factor in supporting healthy nerve function in individuals with polyneuropathy.* NeuRemedy is the leader in the field with thousands of physicians and patients relying each day on its efficacy, purity, safety and rapid onset of action.*

For more information on NeuRemedy, in the USA, contact Realm Labs at 866-634-2745.
In Canada contact OHI at 855-561-4156.

Leave a Reply

Your email address will not be published. Required fields are marked *